Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
作者信息
Van Gool Stefaan W, Makalowski Jennifer, Kampers Linde F C, Van de Vliet Peter, Sprenger Tobias, Schirrmacher Volker, Stücker Wilfried
机构信息
Immun-Onkologisches Zentrum Köln, Köln, Germany.
出版信息
Transl Cancer Res. 2023 Aug 31;12(8):2224-2228. doi: 10.21037/tcr-23-603. Epub 2023 Jul 28.
Abstract
摘要
相似文献
1
Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
Transl Cancer Res. 2023 Aug 31;12(8):2224-2228. doi: 10.21037/tcr-23-603. Epub 2023 Jul 28.
2
DCVax®-L--developed by Northwest Biotherapeutics.
Hum Vaccin Immunother. 2014;10(11):3139-45. doi: 10.4161/hv.29276.
3
DCVax-Brain and DC vaccines in the treatment of GBM.
Expert Opin Investig Drugs. 2009 Apr;18(4):509-19. doi: 10.1517/13543780902841951.
4
Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model.
J Neurooncol. 2023 May;163(1):173-183. doi: 10.1007/s11060-023-04324-4. Epub 2023 May 2.
5
Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana?
Neuro Oncol. 2023 Apr 6;25(4):631-634. doi: 10.1093/neuonc/noac281.
6
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
J Transl Med. 2018 May 29;16(1):142. doi: 10.1186/s12967-018-1507-6.
7
DCVax-L Vaccination in Patients with Glioblastoma: Real Promise or Negative Trial? The Debate Is Open.
Cancers (Basel). 2023 Jun 20;15(12):3251. doi: 10.3390/cancers15123251.
8
Technology evaluation: DCVax, Northwest Biotherapeutics.
Curr Opin Mol Ther. 2002 Aug;4(4):403-7.
9
Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma: What happened to the evidence?
Rev Neurol (Paris). 2023 Jun;179(5):502-505. doi: 10.1016/j.neurol.2023.03.014. Epub 2023 Apr 1.
10
Advances and challenges: dendritic cell vaccination strategies for glioblastoma.
Expert Rev Vaccines. 2017 Jan;16(1):27-36. doi: 10.1080/14760584.2016.1218762. Epub 2016 Aug 10.
引用本文的文献
1
Advancing vaccine-based immunotherapy in glioblastoma treatment.
Neurooncol Adv. 2025 Jun 24;7(1):vdaf135. doi: 10.1093/noajnl/vdaf135. eCollection 2025 Jan-Dec.
2
Therapeutic Efficacy of CD34-Derived Allogeneic Dendritic Cells Engineered to Express CD93, CD40L, and CXCL13 in Humanized Mouse Models of Pancreatic Cancer.
Vaccines (Basel). 2025 Jul 12;13(7):749. doi: 10.3390/vaccines13070749.
3
The Complexity of Malignant Glioma Treatment.
Cancers (Basel). 2025 Mar 4;17(5):879. doi: 10.3390/cancers17050879.
4
Preclinical evaluation of DC-CIK cells as potentially effective immunotherapy model for the treatment of glioblastoma.
Sci Rep. 2025 Jan 3;15(1):734. doi: 10.1038/s41598-024-84284-5.
5
Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature.
Clin Transl Oncol. 2024 Dec 23. doi: 10.1007/s12094-024-03830-9.
6
Current Combinatorial Therapeutic Aspects: The Future Prospect for Glioblastoma Treatment.
Curr Med Sci. 2024 Dec;44(6):1175-1184. doi: 10.1007/s11596-024-2950-7. Epub 2024 Dec 19.
7
Updates in Immunotherapy for Pancreatic Cancer.
J Clin Med. 2024 Oct 26;13(21):6419. doi: 10.3390/jcm13216419.
8
The tumour microenvironment, treatment resistance and recurrence in glioblastoma.
J Transl Med. 2024 Jun 6;22(1):540. doi: 10.1186/s12967-024-05301-9.
9
Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives.
Cancers (Basel). 2024 Mar 25;16(7):1276. doi: 10.3390/cancers16071276.
本文引用的文献
1
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience.
Cancers (Basel). 2023 Feb 13;15(4):1194. doi: 10.3390/cancers15041194.
2
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
JAMA Oncol. 2023 Jan 1;9(1):112-121. doi: 10.1001/jamaoncol.2022.5370.
3
Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis.
Curr Oncol. 2022 Feb 4;29(2):881-891. doi: 10.3390/curroncol29020075.
4
Clinical endpoints in oncology - a primer.
Am J Cancer Res. 2021 Apr 15;11(4):1121-1131. eCollection 2021.
5
Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?
Neurooncol Adv. 2021 Feb 26;3(1):vdab008. doi: 10.1093/noajnl/vdab008. eCollection 2021 Jan-Dec.
6
Clinical trials using oncolytic viral therapy to treat adult glioblastoma: a progress report.
Neurosurg Focus. 2021 Feb;50(2):E3. doi: 10.3171/2020.11.FOCUS20860.
7
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged.
Cancers (Basel). 2020 Dec 24;13(1):32. doi: 10.3390/cancers13010032.
8
Efficacy and safety of dendritic cell vaccines for patients with glioblastoma: A meta-analysis of randomized controlled trials.
Int Immunopharmacol. 2020 Jun;83:106336. doi: 10.1016/j.intimp.2020.106336. Epub 2020 Mar 23.
9
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.
Cancer Immunol Immunother. 2020 Jul;69(7):1191-1204. doi: 10.1007/s00262-020-02534-7. Epub 2020 Mar 6.
10
Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy.
Anticancer Res. 2019 Apr;39(4):2043-2051. doi: 10.21873/anticanres.13315.
Zotero 插件